Novartis Bone Drug Action Doomed By Statute Of Limitations

Law360, New York (March 16, 2012, 9:04 PM EDT) -- A New Jersey state judge on Friday dismissed a product liability suit against Novartis Pharmaceuticals Corp. over its bone drug Zometa, citing a recent Virginia Supreme Court decision affirming that claims in a similar suit are barred by the state's statute of limitations.

In the New Jersey suit, Virginia resident Charles Irby claimed Zometa caused him to develop osteonecrosis — also known as “bone death” — of the jaw, and he sought punitive damages from Novartis. He was diagnosed with the condition in December 2003 and...
To view the full article, register now.